These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21822913)

  • 1. Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study.
    Hesketh PJ; Wright O; Rosati G; Russo M; Levin J; Lane S; Moiseyenko V; Dube P; Kopp M; Makhson A
    Support Care Cancer; 2012 Jul; 20(7):1471-8. PubMed ID: 21822913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
    Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM
    Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
    Herrstedt J; Apornwirat W; Shaharyar A; Aziz Z; Roila F; Van Belle S; Russo MW; Levin J; Ranganathan S; Guckert M; Grunberg SM
    J Clin Oncol; 2009 Nov; 27(32):5363-9. PubMed ID: 19805683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy.
    Gridelli C; Haiderali AM; Russo MW; Blackburn LM; Lykopoulos K
    Support Care Cancer; 2010 Nov; 18(11):1437-44. PubMed ID: 19882176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting.
    Roila F; Rolski J; Ramlau R; Dediu M; Russo MW; Bandekar RR; Grunberg SM
    Ann Oncol; 2009 Nov; 20(11):1867-73. PubMed ID: 19541792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
    Tienchaiananda P; Nipondhkit W; Maneenil K; Sa-Nguansai S; Payapwattanawong S; Laohavinij S; Maneechavakajorn J
    Ann Palliat Med; 2019 Sep; 8(4):372-380. PubMed ID: 31500422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone.
    Johnson B; Adams L; Lu E; Zhang K; Lebowitz P; Lates C; Blum R
    Support Care Cancer; 2009 Sep; 17(9):1177-85. PubMed ID: 19205755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
    Lindley C; Goodin S; McCune J; Kane M; Amamoo MA; Shord S; Pham T; Yowell S; Laliberte K; Schell M; Bernard S; Socinski MA
    Am J Clin Oncol; 2005 Jun; 28(3):270-6. PubMed ID: 15923800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.
    Ithimakin S; Theeratrakul P; Laocharoenkiat A; Nimmannit A; Akewanlop C; Soparattanapaisarn N; Techawattanawanna S; Korphaisarn K; Danchaivijitr P
    Support Care Cancer; 2020 Nov; 28(11):5335-5342. PubMed ID: 32128615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK).
    Joss RA; Bacchi M; Buser K; Kirchner V; Neuenschwander H; Orth B; Aapro MS; Thürlimann B
    Ann Oncol; 1994 Mar; 5(3):253-8. PubMed ID: 8186174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy.
    Italian Group for Antiemetic Research
    N Engl J Med; 2000 May; 342(21):1554-9. PubMed ID: 10824073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.
    Lofters WS; Pater JL; Zee B; Dempsey E; Walde D; Moquin JP; Wilson K; Hoskins P; Guevin RM; Verma S; Navari R; Krook JE; Hainsworth J; Palmer M; Chin C
    J Clin Oncol; 1997 Aug; 15(8):2966-73. PubMed ID: 9256141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.
    Olver I; Paska W; Depierre A; Seitz JF; Stewart DJ; Goedhals L; McQuade B; McRae J; Wilkinson JR
    Ann Oncol; 1996 Nov; 7(9):945-52. PubMed ID: 9006746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Vimolchalao V; Sakdejayont S; Wongchanapai P; Sukprakun S; Angspatt P; Thawinwisan W; Chenaksara P; Sriuranpong V; Vinayanuwatikun C; Parinyanitikun N; Poovorawan N; Tanasanvimon S
    Int J Clin Oncol; 2020 Feb; 25(2):396-402. PubMed ID: 31776732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice.
    Ithimakin S; Runglodvatana K; Nimmannit A; Akewanlop C; Srimuninnimit V; Keerativitayanan N; Soparattanapaisarn N; Laocharoenkeat A
    Support Care Cancer; 2012 Apr; 20(4):849-55. PubMed ID: 21505898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial.
    Bakhshi S; Batra A; Biswas B; Dhawan D; Paul R; Sreenivas V
    Support Care Cancer; 2015 Nov; 23(11):3229-37. PubMed ID: 25851802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.
    Rapoport BL; Jordan K; Boice JA; Taylor A; Brown C; Hardwick JS; Carides A; Webb T; Schmoll HJ
    Support Care Cancer; 2010 Apr; 18(4):423-31. PubMed ID: 19568773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting.
    Meiri E; Jhangiani H; Vredenburgh JJ; Barbato LM; Carter FJ; Yang HM; Baranowski V
    Curr Med Res Opin; 2007 Mar; 23(3):533-43. PubMed ID: 17355735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21.
    Kim HJ; Shin SW; Song EK; Lee NR; Kim JS; Ahn JS; Yun HJ; Cho YH; Park KU; Kim SY; Jang JS; Kim SW; Lee HW; Lee SR; Kim YS; Lee SN; Ko YH; Kim HJ; Kang JH
    Oncologist; 2015 Dec; 20(12):1440-7. PubMed ID: 26512046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.